GlassScriptPhysician profile
Jacob Walker Alhashimi
NPI 1932869864
$1,783.21
in general payments reported to CMS, 2019-2025
26 companies · $528 in 2025
The $528 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $52.90 · 2023: $626 · 2024: $576 · 2025: $528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,730.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,730.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $402.54 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $178.05 | 2023-2025 | Otezla, Repatha, Evenity |
| Abbvie INC. | $157.57 | 2022-2025 | |
| Exact Sciences Corporation | $113.38 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $105.03 | 2024-2025 | Airsupra, Breztri |
| Otsuka America Pharmaceutical, INC. | $98.89 | 2023-2024 | Rexulti |
| Lilly USA, LLC | $80.55 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $72.28 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $70.67 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.55 | 2023-2025 | Jardiance |
| Axsome Therapeutics, INC. | $48.55 | 2025 | Auvelity |
| Antares Pharma, INC. | $47.56 | 2023-2025 | Xyosted, Tlando, Nocdurna |
| Xeris Pharmaceuticals, INC. | $37.37 | 2022-2025 | Gvoke Hypopen |
| Inspire Medical Systems, INC. | $34.29 | 2024 | Inspire |
| Nevro Corp. | $34.12 | 2023 | Senza |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $30.75 | 2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $29.88 | 2023 | |
| Glaxosmithkline, LLC. | $29.58 | 2024 | Shingrix, Arexvy |
| Astellas Pharma US INC | $26.22 | 2023 | Veozah |
| Corcept Therapeutics | $25.66 | 2025 | Korlym |
| Acadia Pharmaceuticals INC | $23.42 | 2025 | Daybue |
| Sumitomo Pharma America, INC. | $17.11 | 2025 | Gemtesa |
| Eisai INC. | $16.71 | 2024 | |
| Sanofi-Aventis U.S. LLC | $15.17 | 2023 | |
| Halozyme INC | $13.45 | 2023 | |
| Pharmacosmos Therapeutics INC. | $12.86 | 2023 | Monoferric |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Alhashimi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.